Business Context and Reporting Period
This Form 8-K was filed by Riot Blockchain, Inc. (formerly Bioptix, Inc.) on October 5, 2017. The filing serves as a Regulation FD disclosure to correct information regarding the company's life sciences segment and to introduce an investor presentation detailing its blockchain business.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on operational corrections and strategic licensing agreements rather than reporting period financial results.
Material Changes and Operational Updates
- Correction of Life Sciences Status: The company corrected a prior interview statement claiming it had shuttered its life sciences operations. Instead, it maintains an Exclusive License Agreement with Ceva Santé Animale S.A. until December 31, 2028, for reproductive hormone products (LH/FSH) for cattle, equine, and swine.
- Licensing Revenue Potential: The agreement includes royalties at low double-digit rates and milestone payments totaling up to $1.1 million, with an additional potential of $2 million for regulatory approvals of specified products.
- BiOptix Diagnostics (BDI) Status: The company has significantly reduced costs by scaling back development and marketing of its BDI SPR platform. It is currently negotiating the sale of BDI business assets and equipment but has not completed the transaction.
- Blockchain Expansion: The company highlighted its investment in goNumerical Ltd. (Coinsquare Ltd.), a leading Canadian digital currency exchange, marking a strategic pivot toward blockchain operations.
Guidance, Outlook, and Risks
Management commentary indicates a dual-track strategy: monetizing the life sciences segment through licensing and asset sales while expanding into the blockchain sector. The filing notes that the company is in active negotiations to sell BDI assets and assume certain liabilities, representing a contingency that has not yet been finalized. No specific financial guidance or forward-looking revenue projections were included in this text.
Investor Verification Checklist
- Verify the status and terms of the Exclusive License Agreement with Ceva Santé Animale S.A.
- Confirm the progress of negotiations regarding the sale of BiOptix Diagnostics, Inc. assets.
- Review the detailed Investor Presentation (Exhibit 99.1) for specifics on the goNumerical/Coin square investment.
- Check subsequent filings for the completion of the BDI asset sale and any realized milestone payments.